Back to today’s briefing

Story perspectives

FDA Approves New Hope for KRAS G12C-Colorectal Cancer

1/18/2025

45 8

Summary

Story summary

On January 16, 2025, the FDA greenlit the groundbreaking combination of sotorasib and panitumumab for treating KRAS G12C-mutated colorectal cancer. This innovative therapy offers hope, demonstrating enhanced progression-free survival over traditional treatments. With KRAS G12C mutations impacting 3-4% of metastatic patients and often leading to grim prognoses, this approval marks a significant step forward in cancer care.

1 of 1

Story summary

On January 16, 2025, the FDA greenlit the groundbreaking combination of sotorasib and panitumumab for treating KRAS G12C-mutated colorectal cancer. This innovative therapy offers hope, demonstrating enhanced progression-free survival over traditional treatments. With KRAS G12C mutations impacting 3-4% of metastatic patients and often leading to grim prognoses, this approval marks a significant step forward in cancer care.